Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Urology

Search Medical Condition
Please enter condition
Please choose location

Bladder Carcinoma Clinical Trials

A listing of Bladder Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (99) clinical trials

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Primary Objective To estimate the proportion of patients with pathological downstaging to

Phase

A Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma

Study Drug Administration: Within 7 to 14 days before your first dose of pemetrexed: - You will start a vitamin pill (folic acid) at least 7 days before the first dose of study drug. You will continue to take this drug while you are receiving treatment. Folic acid has been ...

Phase

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

This is a multinational cohort database study to estimate the incidence of female breast cancer and bladder cancer, by insulin use at cohort entry, in patients who are prescribed dapagliflozin compared to patients prescribed other specific oral antidiabetic drugs. Dapagliflozin and other antidiabetic drugs are used to treat type 2 ...

Phase N/A

Genetic Predictors of Benefit to Pembrolizumab

The adaptive immune response mechanism can be co-opted by tumor cells leading to immune resistance and tumor growth. Recent success of anti-PD-1 antibodies (anti-PD-1) across a broad range of tumors suggests that this immune resistance can be reversed. Although responses have been observed to anti-PD-1, it is a subset of ...

Phase

Safety and Tolerability of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

The purpose of this study is to determine if GemRIS, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis and transurethral resection of bladder tumors (TURBT)

Phase

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between diagnosis and radical cystectomy (RC).

Phase

Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

Patients with T2-T4a N0 urothelial bladder carcinoma (UBC) with residual disease after transurethral resection of the bladder (TURB, surgical opinion, cystoscopy or radiological presence) will receive 3 cycles of pembrolizumab (MK-3475) at the dose of 200mg 3 weekly prior to surgery (radical cystectomy). Cystectomy will be planned to be done ...

Phase

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Gu rin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

This Phase Ib/II study is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, patient reported outcomes (PROs), and preliminary anti-tumor activity of atezolizumab administered by intravenous (IV) infusion alone and in combination with intravesical BCG in high-risk NMIBC participants. The study will be conducted in following cohorts: Cohort 1A, Cohort ...

Phase

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

Neuromuscular blockade (NMB) is frequently utilized in laparoscopic procedures to improve surgical conditions by relaxing the abdominal muscles and thus facilitating insufflation with carbon dioxide to optimize surgical view. Increased airway pressures can lead to an increase in alveolar and perivascular edema, a decline in dynamic lung compliance and hypoxemia. ...

Phase

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma, esophageal cancer and malignant melanoma. Patients must be positive for HLA-A*02:01 or HLA-A*02:06 and the ...

Phase